NCT01269437 - Efficacy and Safety Study of Budesonide Novolizer Dry Powder Inhaler 200μg to Treat Chinese Patients With Mild to Moderate Asthma | Biotech Hunter

Enrollment

332

Participants

Timeline

Start Date

December 31, 2010

Primary Completion Date

October 31, 2011

Study Completion Date

October 31, 2011

Conditions

Asthma

Interventions

DRUG

Budesonide dry powder inhaler

200mcg per inhalation, twice daily, for 12 weeks

Trial Locations (11)

RECRUITING

The Second Artillery General Hospital of PLA, Beijing

RECRUITING

The First Affiliated Hospital of Foshan, Foshan

RECRUITING

Guangzhou First Municipal People's Hospital, Guangzhou

RECRUITING

The First Affiliated Hospital of Guangzhou Medical College, Guangzhou Institute of Respiratory Disease, Guangzhou

RECRUITING

Zhongda Hospital of Southeast University, Nanjing

RECRUITING

Shengjing Hospital, Shenyang

RECRUITING

Dongfang Hospital Affiliated to Tongji University, Shanghai

RECRUITING

Putuo District Hospital, Shanghai

WITHDRAWN

Shanghai Pulmonary Hospital, Shanghai

RECRUITING

Zhongshan Hospital affiliated to Fudan University, Shanghai

RECRUITING

The General Hospital of Shenyang Military Region, Shenyang